Literature DB >> 24255891

Acute renal artery occlusion following infliximab infusion.

Caroline Lemaitre1, Isabelle Iwanicki-Caron, Clément De Vecchi, Nathalie Bertiaux-Vandaële, Guillaume Savoye.   

Abstract

We report the case of a 44-year-old male patient who presented with acute renal artery occlusion, 3 d after first injection of infliximab for steroid refractory attack of ulcerative colitis. Extensive work-up provided no evidence of predisposing factors for arterial thrombosis. Infliximab was thus suspected in the genesis of thrombosis, based on both intrinsic and extrinsic criteria. At month 3 after thrombosis with ongoing anticoagulation, angio-tomodensitometry showed complete revascularization of the left renal artery with renal atrophy. Renal function remained normal and the patient was still in steroid free remission on mercaptopurin monotherapy at maximal follow-up. Few thromboembolic events have been described with anti- tumor necrosis factor (TNF) agents, but it is the first case reported of renal artery thrombosis after infliximab infusion. In addition, we review thrombosis associated with anti-TNF agents.

Entities:  

Keywords:  Acute renal artery occlusion; Anti-tumor necrosis factor agent; Infliximab; Ulcerative colitis

Year:  2013        PMID: 24255891      PMCID: PMC3832916          DOI: 10.5527/wjn.v2.i3.90

Source DB:  PubMed          Journal:  World J Nephrol        ISSN: 2220-6124


  18 in total

1.  Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

Authors:  T Jonsdottir; J Forslid; A van Vollenhoven; A Harju; S Brannemark; L Klareskog; R F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2004-04-05       Impact factor: 19.103

2.  Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study.

Authors:  Matthew J Grainge; Joe West; Timothy R Card
Journal:  Lancet       Date:  2010-02-08       Impact factor: 79.321

3.  Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.

Authors:  L A Korswagen; G M Bartelds; C L M Krieckaert; F Turkstra; M T Nurmohamed; D van Schaardenburg; C A Wijbrandts; P P Tak; W F Lems; B A C Dijkmans; R M van Vugt; G J Wolbink
Journal:  Arthritis Rheum       Date:  2011-04

4.  Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.

Authors:  M A Gonzalez-Gay; M T Garcia-Unzueta; J M De Matias; C Gonzalez-Juanatey; C Garcia-Porrua; A Sanchez-Andrade; J Martin; J Llorca
Journal:  Clin Exp Rheumatol       Date:  2006 Jul-Aug       Impact factor: 4.473

Review 5.  Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention.

Authors:  Naamah L Zitomersky; Menno Verhave; Cameron C Trenor
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

6.  Risk factors and clinical impact of postoperative symptomatic venous thromboembolism.

Authors:  Chethan Gangireddy; John R Rectenwald; Gilbert R Upchurch; Thomas W Wakefield; Shukri Khuri; William G Henderson; Peter K Henke
Journal:  J Vasc Surg       Date:  2007-02       Impact factor: 4.268

7.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Authors:  P J Charles; R J Smeenk; J De Jong; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  2000-11

Review 8.  Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.

Authors:  Gianfranco Ferraccioli; Elisa Gremese
Journal:  Autoimmun Rev       Date:  2004-06       Impact factor: 9.754

9.  Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice.

Authors:  T Meyer; L Robles-Carrillo; T Robson; F Langer; H Desai; M Davila; M Amaya; J L Francis; A Amirkhosravi
Journal:  J Thromb Haemost       Date:  2008-10-30       Impact factor: 5.824

Review 10.  Autoimmune diseases induced by TNF-targeted therapies.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Maria-Jose Soto; Maria-Jose Cuadrado; Munther A Khamashta
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-10       Impact factor: 4.098

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.